Cue Biopharma, Inc

CUE-101 and KEYTRUDA® (pembrolizumab) showed 46% ORR, 91.3% 12-month OS, and 21.8 months mOS in 1L HPV+ R/M HNSCC patients. CUE-101 and pembrolizumab achieved 50% ORR in 1L patients with low PD-L1 expression. CUE-102 monotherapy demonstrated 67% DCR in late-stage pancreatic cancer, including a 40% tumor burden decrease. CUE-101 data presented at SITC 2024.

CUE-101 and KEYTRUDA® (pembrolizumab) in 1L HPV+ R/M HNSCC patients: ORR of 46%, 12-month OS of 91.3%, mOS of 21.8 months. ORR of 50% in 1L patients with low PD-L1 expression. 67% DCR in late-stage pancreatic cancer patients treated with CUE-102 monotherapy, including an unconfirmed PR with a 40% decrease in tumor burden. Data presented at SITC 2024.

Cue Biopharma presented updated Phase 1 data for CUE-101 and CUE-102 at SITC 2024, showing CUE-101 with KEYTRUDA achieved a 46% objective response rate and 91.3% 12-month overall survival in head and neck cancer patients, with a median overall survival of 21.8 months. CUE-102 demonstrated a 67% disease control rate in late-stage pancreatic cancer patients, including a partial response with 40% tumor reduction. Both treatments had favorable safety profiles.